Repare Therapeutics is a leading clinical-stage precision oncology company enabled by our proprietary synthetic lethality approach to discovering and developing novel therapeutics. We use our genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Our company was founded in 2016 by field-leading academics to systematically employ synthetic lethality insights and platforms and develop new precision oncology medicines. For more information, please visit www.reparerx.com.
View Top Employees from Repare TherapeuticsWebsite | http://www.reparerx.com |
Revenue | $7.8 million |
Funding | $150.5 million |
Employees | 190 (184 on RocketReach) |
Founded | 2016 |
Phone | (857) 412-7018 |
Technologies |
JavaScript,
HTML,
PHP
+24 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Healthcare |
Keywords | Targeted Cancer Therapies, Cancer Research, Drug Development And Manufacturing, Oncology |
Competitors | Applied Biological Materials, Forbius, Fusion Pharmaceuticals, IPA (ImmunoPrecise Antibodies), Turnstone Biologics |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 541 Companies, NAICS Code 32541 Companies, NAICS Code 54 Companies, NAICS Code 3254 Companies |
Looking for a particular Repare Therapeutics employee's phone or email?
The Repare Therapeutics annual revenue was $7.8 million in 2024.
Lloyd Segal is the President and Chief Executive Officer of Repare Therapeutics.
184 people are employed at Repare Therapeutics.
Repare Therapeutics is based in Montreal, Quebec.
The NAICS codes for Repare Therapeutics are [325, 32, 541, 32541, 54, 3254].
The SIC codes for Repare Therapeutics are [283, 28].